A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers. (Q46630423)
Jump to navigation
Jump to search
scientific article published in August 2005
Language | Label | Description | Also known as |
---|---|---|---|
English | A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers. |
scientific article published in August 2005 |
Statements
A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers (English)
Ghassan K Abou-Alfa
Eric K Rowinsky
Gary K Schwartz
David P Kelsen
Sunil Sharma
Eve Siegel
Carlos R Becerra
S Gail Eckhardt
Kevie Feit